[go: up one dir, main page]

DK0513200T3 - Fremgangsmåde og sammensætninger til syntese af BCH-189 og beslægtede forbindelser - Google Patents

Fremgangsmåde og sammensætninger til syntese af BCH-189 og beslægtede forbindelser

Info

Publication number
DK0513200T3
DK0513200T3 DK91904454T DK91904454T DK0513200T3 DK 0513200 T3 DK0513200 T3 DK 0513200T3 DK 91904454 T DK91904454 T DK 91904454T DK 91904454 T DK91904454 T DK 91904454T DK 0513200 T3 DK0513200 T3 DK 0513200T3
Authority
DK
Denmark
Prior art keywords
bch
related compounds
synthesis
compositions
methods
Prior art date
Application number
DK91904454T
Other languages
English (en)
Other versions
DK0513200T4 (da
Inventor
Dennis C Liotta
Woo-Baeg Choi
Raymond F Schinazi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23879071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0513200(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Emory filed Critical Univ Emory
Publication of DK0513200T3 publication Critical patent/DK0513200T3/da
Application granted granted Critical
Publication of DK0513200T4 publication Critical patent/DK0513200T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
DK91904454T 1990-02-01 1991-01-31 Fremgangsmåde og sammensætninger til syntese af BCH-189 og beslægtede forbindelser DK0513200T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/473,318 US5204466A (en) 1990-02-01 1990-02-01 Method and compositions for the synthesis of bch-189 and related compounds
PCT/US1991/000685 WO1991011186A1 (en) 1990-02-01 1991-01-31 Method and compositions for the synthesis of bch-189 and related compounds

Publications (2)

Publication Number Publication Date
DK0513200T3 true DK0513200T3 (da) 1999-05-25
DK0513200T4 DK0513200T4 (da) 2004-07-05

Family

ID=23879071

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98201737T DK0872237T3 (da) 1990-02-01 1991-01-31 Fremgangsmåde og sammensætninger til syntese af BCH-189 og beslægtede forbindelser
DK91904454T DK0513200T4 (da) 1990-02-01 1991-01-31 Fremgangsmåde og sammensætninger til syntese af BCH-189 og beslægtede forbindelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98201737T DK0872237T3 (da) 1990-02-01 1991-01-31 Fremgangsmåde og sammensætninger til syntese af BCH-189 og beslægtede forbindelser

Country Status (22)

Country Link
US (8) US5204466A (da)
EP (3) EP0513200B2 (da)
JP (6) JPH07618B2 (da)
KR (2) KR100188357B1 (da)
AT (1) ATE170750T1 (da)
AU (6) AU658136C (da)
BG (1) BG62236B1 (da)
CA (3) CA2075189C (da)
DE (4) DE69130166T3 (da)
DK (2) DK0872237T3 (da)
ES (2) ES2076130T5 (da)
FI (4) FI114471B (da)
GR (1) GR950300024T1 (da)
HK (1) HK1014664A1 (da)
HU (4) HU227485B1 (da)
LU (1) LU91073I2 (da)
MC (1) MC2233A1 (da)
NL (1) NL300148I2 (da)
NO (6) NO923014D0 (da)
RO (1) RO108564B1 (da)
RU (1) RU2125558C1 (da)
WO (1) WO1991011186A1 (da)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
PT674634E (pt) * 1989-02-08 2003-09-30 Iaf Biochem Int Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
US20090239887A1 (en) * 1990-02-01 2009-09-24 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
DE19514523A1 (de) * 1995-04-12 1996-10-17 Schering Ag Neue Cytosin- und Cytidinderivate
EP0831852B1 (en) 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
DE69727240T2 (de) 1996-06-25 2004-11-25 Glaxo Group Ltd., Greenford Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
WO1998041522A1 (en) * 1997-03-19 1998-09-24 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
WO1998044913A2 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
JP2002504558A (ja) 1998-02-25 2002-02-12 エモリー ユニバーシテイ ２’−フルオロヌクレオシド
EP1754710A3 (en) 1998-02-25 2007-12-19 Emory University 2'-Fluoroncucleosides
PT1431304E (pt) * 1998-08-10 2015-03-09 Novartis Ag Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
PT1104415E (pt) 1998-08-12 2005-03-31 Univ Emory Metodo de preparacao de nucleosidos de 1,3-oxatiolano
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
EP1380303B1 (en) * 1998-11-02 2008-09-17 Gilead Sciences, Inc. Combination therapy to treat hepatitis B virus
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
BR9915555A (pt) 1998-11-05 2002-01-15 Centre Nat Rech Scient Composto, composição e uso de ß - l- (2' ou 3' -azido) - 2', 3' -didesóxi -5-flúor citosina para o tratamento de infecção por vìrus de hepatite b
ES2209532T3 (es) 1998-12-23 2004-06-16 Shire Biochem Inc. Analogos de nucleosidos antivirales.
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
TR200601783T2 (tr) * 1999-11-12 2007-01-22 Pharmasset Ltd 2'-Deoksi-L-nükleositlerin sentezi
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002011668A2 (en) * 2000-08-09 2002-02-14 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US20030166606A1 (en) * 2000-08-09 2003-09-04 Kwan-Hee Kim 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
CA2426187C (en) 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
WO2002070518A1 (en) * 2001-03-01 2002-09-12 Triangle Pharmaceuticals, Inc. Polymorphic and other crystalline forms of cis-ftc
CA2380804A1 (en) * 2001-05-01 2002-11-01 Mitsui Chemicals, Inc. Method for producing cytosine nucleosides compounds
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
ITMI20012317A1 (it) * 2001-11-06 2003-05-06 Recordati Ind Chimica E Farma Processo diastereoselettivo per la preparazione del'agente antivirale4-amino-1-(2r-idrossimetil-/1,3/ossatiolan-5s-i1)-1h-pirimidin-2-one
CN1620295A (zh) * 2001-12-14 2005-05-25 法玛塞特有限公司 制备用于合成抗病毒核苷的中间体
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
MXPA04009986A (es) * 2002-04-12 2005-08-16 Achillion Pharmaceuticals Inc Metodo para sintetizar beta-l-5-fluoro-2¦,3¦-didesoxi-2¦,3¦-dideshidrocitidina (¦-l-fd4c).
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0312278A (pt) * 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
BR0313302A (pt) 2002-08-06 2005-06-28 Pharmasset Inc Processos para a preparação de nucleosìdeos de 1,3-dioxolano
HUE027522T2 (en) * 2002-09-13 2016-11-28 Novartis Ag ß-L-2'-Deoxynucleosides for treatment of resistant HBV strains and for combination therapies
PL377342A1 (pl) * 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
AU2003296360A1 (en) * 2002-12-09 2004-06-30 Emory University Dioxolane thymine and combinations for use against 3tc/ azt resistant strains of hiv
ES2470771T3 (es) * 2002-12-12 2014-06-24 Idenix Pharmaceuticals, Inc Procedimiento para la producción de nucle�sidos ramificados en 2'
ATE398455T1 (de) * 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
KR20060035652A (ko) * 2003-06-30 2006-04-26 이데닉스 (케이만) 리미티드 β-Ｌ-2-데옥시 뉴클레오시드의 합성
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
BRPI0507363A (pt) * 2004-02-03 2007-07-03 Univ Emory métodos para manufatura de 1,3-dioxolano nucleosìdeos
PL1778251T3 (pl) 2004-07-27 2011-09-30 Gilead Sciences Inc Koniugaty fosfonianowo-nukleozydowe jako środki przeciw wirusowi HIV
JP4058057B2 (ja) * 2005-04-26 2008-03-05 株式会社東芝 日中機械翻訳装置、日中機械翻訳方法および日中機械翻訳プログラム
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2625047A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2007075876A2 (en) * 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1979370B1 (en) * 2006-01-17 2010-03-17 N.V. Organon SELECTIVE ENZYMATIC HYDROLYSIS OF C-TERMINAL tert-BUTYL ESTERS OF PEPTIDES
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ATE485292T1 (de) * 2006-04-18 2010-11-15 Lupin Ltd Neue kristalline form von lamivudin
WO2008010921A2 (en) 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
EP2089384B1 (en) 2006-12-13 2015-08-05 F. Hoffmann-La Roche AG 2-(piperidin-4-yl)-4-phenoxy-or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
KR101577698B1 (ko) * 2007-02-23 2015-12-15 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
CN101307048B (zh) * 2007-05-18 2011-03-23 上海迪赛诺医药发展有限公司 立体选择性制备拉米夫定的方法
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
WO2009009625A2 (en) 2007-07-09 2009-01-15 Eastern Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties
WO2009052050A1 (en) * 2007-10-15 2009-04-23 Pharmasset, Inc. Dioxolane thymine phosphoramidates as anti-hiv agents
US20100311961A1 (en) * 2007-11-29 2010-12-09 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1,3-oxathiolanes, especially lamivudine
BRPI0820226A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Processo para o preparo de um 1,3-oxatiolana, para o preparo de lamivudina e para isolar lamivudina, lamivudina e composição farmacêutica
EP2258709A1 (en) 2008-02-29 2010-12-08 Kaneka Corporation 2'-hydroxyl-protected ribonucleoside derivative and manufacturing method of same
EP2350065A1 (en) * 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
AP2011005745A0 (en) 2008-12-09 2011-06-30 Gilead Sciences Inc Modulators of toll-like receptors.
US20110282046A1 (en) 2009-01-19 2011-11-17 Rama Shankar Process for preparation of cis-nucleoside derivative
KR101474570B1 (ko) 2009-04-13 2014-12-19 주식회사 대희화학 라미부딘의 신규한 중간체 및 이의 제조방법
EP2435825B8 (en) 2009-05-27 2015-09-02 Biotempus Limited Methods of treating diseases
EP2454244B1 (en) 2009-07-15 2013-06-26 Lupin Limited An improved process for preparation of efavirenz
WO2011095987A1 (en) 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
CN102584800A (zh) * 2011-12-16 2012-07-18 四川大学 手性吲哚酮和当归内酯骨架化合物及不对称合成
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
SI3235824T1 (sl) * 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
TWI752457B (zh) 2012-12-21 2022-01-11 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
NO2865735T3 (da) 2013-07-12 2018-07-21
WO2015028875A2 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (da) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
PL3166607T3 (pl) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
GB201610327D0 (en) * 2016-06-14 2016-07-27 Univ Nelson Mandela Metropolitan Process for producing Lamivudine and Entricitabine
EP3601301A1 (en) * 2017-03-31 2020-02-05 The University of Liverpool Prodrug compositions
JP2021509907A (ja) 2018-01-09 2021-04-08 リガンド・ファーマシューティカルズ・インコーポレイテッド アセタール化合物およびその治療的使用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) * 1975-11-10 1977-05-16 Asahi Chem Ind Co Ltd Preparation of uracil derivatives
JPS6045196B2 (ja) * 1976-08-09 1985-10-08 株式会社興人 １−（２−テトラヒドロフリル）ウラシル類の製造方法
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
JPS5839672A (ja) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
DE3481191D1 (de) * 1983-07-20 1990-03-08 Teijin Ltd Antineoplastisches mittel.
DE3534979A1 (de) * 1985-07-25 1987-01-29 Licentia Gmbh Netzgeraet
AU570853B2 (en) * 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
EP0342203B1 (en) * 1987-03-24 1994-07-06 Nycomed Imaging As 2',3' dideoxyribofuranoxide derivatives
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5011774A (en) * 1987-07-17 1991-04-30 Bristol-Myers Squibb Co. Dideoxyinosine by enzymatic deamination of dideoxyadenosine
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
CA1318627C (en) * 1988-07-14 1993-06-01 Jeffrey M. Howell Enzymatic resolution process
US5106750A (en) * 1988-08-30 1992-04-21 G. D. Searle & Co. Enantio- and regioselective synthesis of organic compounds using enol esters as irreversible transacylation reagents
JPH0269476A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ピリミジン誘導体の製法
JPH0269469A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ジヒドロフラン誘導体及びその製法
GB8822546D0 (en) * 1988-09-26 1988-11-02 Wellcome Found Antiviral combinations
EP0375329B1 (en) * 1988-12-19 1995-05-31 The Wellcome Foundation Limited Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them
PT674634E (pt) * 1989-02-08 2003-09-30 Iaf Biochem Int Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
CA2023856A1 (en) * 1989-09-26 1991-03-27 Jeffrey M. Howell Enzymatic resolution process
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
SE510803C2 (sv) * 1994-12-13 1999-06-28 Volvo Ab Tryckmediepåverkad manöveranordning
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer

Also Published As

Publication number Publication date
HK1014664A1 (en) 1999-09-30
AU658136B2 (en) 1995-04-06
AU698859B2 (en) 1998-11-12
JPH07618B2 (ja) 1995-01-11
KR100188357B1 (ko) 1999-06-01
EP0513200A4 (en) 1993-04-07
BG62236B1 (bg) 1999-06-30
JP3844978B2 (ja) 2006-11-15
AU4474599A (en) 1999-11-11
EP0872237B1 (en) 2007-01-17
AU698859C (en) 2003-01-30
HU227485B1 (en) 2011-07-28
DE122004000015I1 (de) 2004-08-12
JPH05505794A (ja) 1993-08-26
NO970385D0 (no) 1997-01-29
NO970385L (no) 1992-07-30
HU9202496D0 (en) 1992-12-28
FI114471B (fi) 2004-10-29
ES2076130T3 (es) 1999-03-01
ES2076130T1 (es) 1995-11-01
FI121069B (fi) 2010-06-30
NO326249B1 (no) 2008-10-27
NL300148I2 (nl) 2004-11-01
DE69130166T3 (de) 2005-04-14
EP0513200A1 (en) 1992-11-19
CA2481078C (en) 2009-12-15
AU2006207874A1 (en) 2006-09-28
DE122004000015I2 (de) 2004-11-18
CA2075189A1 (en) 1991-08-02
AU2002300661B2 (en) 2006-06-08
EP0513200B1 (en) 1998-09-09
US20050004148A1 (en) 2005-01-06
NO970386D0 (no) 1997-01-29
NO2008011I2 (no) 2010-10-18
AU2006207874B2 (en) 2010-02-11
US5814639A (en) 1998-09-29
DE69133556D1 (de) 2007-03-08
EP1772151A2 (en) 2007-04-11
DE69133556T2 (de) 2007-08-16
NO20083728L (no) 1992-07-30
US5914400A (en) 1999-06-22
DK0513200T4 (da) 2004-07-05
HU211300A9 (en) 1995-11-28
RO108564B1 (ro) 1994-06-30
JP3530150B2 (ja) 2004-05-24
CA2678778A1 (en) 1991-08-08
ES2076130T5 (es) 2004-12-16
CA2075189C (en) 2004-11-30
FI923446L (fi) 1992-07-30
US5210085A (en) 1993-05-11
AU7300491A (en) 1991-08-21
ATE170750T1 (de) 1998-09-15
EP0513200B2 (en) 2004-04-28
FI20050672L (fi) 2005-06-22
HUT62566A (en) 1993-05-28
JP4496377B2 (ja) 2010-07-07
KR100381705B1 (ko) 2003-04-26
AU658136C (en) 2003-06-12
NL300148I1 (nl) 2004-07-01
CA2481078A1 (en) 1991-08-08
GR950300024T1 (en) 1995-06-30
WO1991011186A1 (en) 1991-08-08
NO20065640L (no) 1992-07-30
FI923446A0 (fi) 1992-07-30
FI20030933A (fi) 2003-06-24
DE513200T1 (de) 1995-07-13
NO970386L (no) 1992-07-30
DE69130166D1 (de) 1998-10-15
JP2005053893A (ja) 2005-03-03
KR920703582A (ko) 1992-12-18
FI116222B (fi) 2005-10-14
AU2010201878A1 (en) 2010-05-27
JP2002012591A (ja) 2002-01-15
NO923014L (no) 1992-07-30
BG96717A (bg) 1993-12-24
US6153751A (en) 2000-11-28
EP0872237A1 (en) 1998-10-21
NO2008011I1 (no) 2008-07-28
US5539116A (en) 1996-07-23
LU91073I2 (fr) 2004-04-23
DE69130166T2 (de) 1999-04-08
US6114343A (en) 2000-09-05
MC2233A1 (fr) 1993-02-23
JP2006141408A (ja) 2006-06-08
EP1772151A3 (en) 2007-06-13
ES2279559T3 (es) 2007-08-16
FI20060622L (fi) 2006-06-27
US5204466A (en) 1993-04-20
JP4108645B2 (ja) 2008-06-25
RU2125558C1 (ru) 1999-01-27
NO923014D0 (no) 1992-07-30
NO313048B1 (no) 2002-08-05
AU4031995A (en) 1996-04-26
JP2001352997A (ja) 2001-12-25
DK0872237T3 (da) 2007-04-23
JP2001019690A (ja) 2001-01-23
NO324979B1 (no) 2008-01-14

Similar Documents

Publication Publication Date Title
DK0513200T3 (da) Fremgangsmåde og sammensætninger til syntese af BCH-189 og beslægtede forbindelser
DK0869131T3 (da) 5-Halogen-5-deoxy-sorbopyranose-forbindelser
DE69105635D1 (de) Dibenzoylalkylcyanohydrazine.
RU92016627A (ru) Способ и составы для синтеза всн-189 и родственных соединений
DK0656379T3 (da) Fremgangsmåde til fremstilling af polyurethangenstande fra uretonimin-baserede sammensætninger